The FY2022-1 Small Business Innovation Research Contract (SBIR) Program solicitation has been posted!
“The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) invite small business concerns (SBCs) to submit research proposals under this Small Business Innovation Research (SBIR) Contract Solicitation. Firms with the capability to conduct research and development (R&D) in any of the health-related topic areas described in Section 12.0, and to commercialize the results of that R&D, are encouraged to participate.”
Please see link above for specific solicitations.
Contract funding is very different from grant funding, and a project needs to be a very (very) good fit to pursue this mechanism. NIAID offers a useful resource to compare differences between grants and contracts – although written specifically for NIAID, these guidelines generally apply across NIH contracts.
Wondering if your company could win non-dilutive funding through an SBIR contract? Have questions about understanding the solicitation details? Reach out today and we will connect you with one of our experts!
The FY2022-1 Small Business Innovation Research Contract (SBIR) Program solicitation has been posted!
“The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) invite small business concerns (SBCs) to submit research proposals under this Small Business Innovation Research (SBIR) Contract Solicitation. Firms with the capability to conduct research and development (R&D) in any of the health-related topic areas described in Section 12.0, and to commercialize the results of that R&D, are encouraged to participate.”
Please see link above for specific solicitations.
Contract funding is very different from grant funding, and a project needs to be a very (very) good fit to pursue this mechanism. NIAID offers a useful resource to compare differences between grants and contracts – although written specifically for NIAID, these guidelines generally apply across NIH contracts.
Wondering if your company could win non-dilutive funding through an SBIR contract? Have questions about understanding the solicitation details? Reach out today and we will connect you with one of our experts!
-
FY2022 NIH SBIR Contract Topics:
TOPIC NUMBER
PHASE I ALLOWED?
FAST TRACK ALLOWED?
(A Phase I proposal and a Phase II proposal submitted simultaneously)
DIRECT TO PHASE II ALLOWED?
(Includes only a Phase II Proposal)
TOPIC TITLE
NIH/NCATS 022
Yes
No
No
Technological Development and Validation of Remote Measures for Use in Clinical Trials in Individuals with Rare Diseases
NIH/NCI 430
Yes
Yes
Yes
Development of Senotherapeutic Agents for Cancer Treatment
NIH/NCI 431
Yes
Yes
Yes
Cancer Treatment Technologies for Low-Resource Settings
NIH/NCI 432
Yes
No
Yes
Synthetic Biology Gene Circuits for Cancer Therapy
NIH/NCI 433
Yes
Yes
Yes
Developing Unbiased Medical Technologies to Reduce Disparities in Cancer Outcomes
NIH/NCI 434
Yes
Yes
Yes
Ultra-Fast Dose Rate (FLASH) Radiation Detectors and Safety Systems
NIH/NCI 435
Yes
Yes
No
Devices to Treat Secondary Lymphedema Following Cancer Treatment
NIH/NCI 436
Yes
Yes
No
New Technologies to Analyze Extra-Chromosomal DNA in Cancer
NIH/NCI 437
Yes
No
Yes
3D Spatial Omics for Molecular and Cellular Tumor Atlas Construction
NIH/NCI 438
Yes
No
No
Understanding Cancer Tumor Genomic Results: Technology Applications for Community Providers
NIH/NCI 439
Yes
No
Yes
Advanced Sample Processing Platforms for Downstream Single-Cell Multi-Omic Analysis
NIH/NCI 440
Yes
Yes
Yes
Cancer Prevention and Diagnosis Technologies for Low-Resource Settings
NIH/NCI 441
Yes
Yes
Yes
At-Home Screening for Hepatitis C Virus
NIH/NCI 442
Yes
No
No
Quantitative Biomarkers as Medical Device Development Tools for Cancer
NIH/NCI 443
Yes
Yes
Yes
Development of Computer-Aided Diagnosis Tools for Upper and Lower Gastrointestinal Tract Cancer Prevention
NIH/NCI 444
Yes
No
No
Evaluation Datasets as Medical Device Development Tools for Testing Cancer Technologies
NIH/NCI 445
Yes
Yes
Yes
Advanced Manufacturing to Speed Availability of Emerging Autologous Cell-based Therapies
NIH/NIA 004
Yes
Yes
Yes
Improving CNS Gene Delivery Systems for AD/ADRD Therapy Development
NIH/NIA 005
Yes
No
No
Geroscience-based Chronic Wound Treatment Product Development
NIH/NIA 006
Yes
Yes
No
The Development of Mechanism-based Adult Stem Cell Treatments to Combat Aging Pathologies
NIH/NIAID 101
Yes
Yes
No
Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines
NIH/NIAID 102
Yes
Yes
No
Genetically Engineered Mice for Pre-clinical Evaluation of HIV Vaccine Candidates
NIH/NIAID 103
Yes
Yes
No
Development of Diagnostics to Differentiate HIV Infection from Vaccine Induced Seropositivity
NIH/NIAID 104
Yes
Yes
Yes
Adjuvant Discovery for Vaccines and for Autoimmune and Allergic Diseases
NIH/NIAID 105
Yes
Yes
Yes
Adjuvant Development for Vaccines and for Autoimmune and Allergic Diseases
NIH/NIAID 106
Yes
Yes
Yes
Production of Adjuvants Mimics
NIH/NIAID 107
Yes
Yes
Yes
Reagents for Immunologic Analysis of Non- mammalian and Underrepresented Mammalian Models
NIH/NIAID 108
Yes
Yes
No
Development of Rapid POC Diagnostics for Treponema pallidum
NIH/NIAID 109
Yes
Yes
No
Development of Monoclonal Antibody-mediated Interventions to Combat Malaria
NIH/NIAID 110
Yes
Yes
No
Point of Care (POC) Diagnostics for Antimicrobial Resistant (AMR) Enteric Bacterial and Parasitic Pathogens
NIH/NIAID 111
Yes
Yes
No
Data Science Tools for Infectious and Immune-mediated Disease Research
NIH/NIAID 112
Yes
Yes
No
Digital Tools Against Misinformation About Infectious Disease Treatments and Vaccines
CDC/NCBDDD 020
Yes
No
No
Open-Source and User-Friendly Record Linkage/De-duplication Tool
CDC/NCCDPHP 044
Yes
No
No
Algorithmic Database Food Product Tool to Align Food Service with Guidelines
CDC/NCEZID 028
Yes
No
No
Development Rapid, Portable, Point-of-Care C. auris Diagnostic
CDC/NCEZID 029
Yes
No
No
Product to Inactivate and Stabilize Wastewater Samples for Shipping and Transport
CDC/NCHHSTP 052
Yes
No
No
Electronic Health Record Algorithm to Identify Persons with HIV Not in Care
CDC/NCHHSTP 053
Yes
No
No
Simultaneous Detection of Molecular and Serological Markers via Next-Generation Sequencing
CDC/NCIRD 035
Yes
No
No
Nanoparticle-based Multi-Antigen Influenza Vaccine that Induces both Antibody and Cell-Mediated Immune Responses
Webinar resources are now available:
Are you ready to get started on winning the non-dilutive funding your company needs?
Recent Comments